BIOMAT Database Logo BIOMAT Database Logo

[Systemic thrombolytic therapy in acute myocardial infarct: its effect on left ventricular function, body oxygen consumption and disease prognosis]. 1993

N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova

Echocardiography, integral rheography of the body, Holter monitoring, assessment of oxygen consumption and blood gases were used in examination of 93 patients with macrofocal myocardial infarction (MI). 48 patients received thrombolytic therapy (TT) within 6 hours of MI which in 27 patients implied standard drugs (streptodecase, celiase, avelysin) and new medicine APSAC (21 patients). 45 patients received no TT. It was found that in acute MI period systemic TT prevented a fall in left ventricular performance, promoted advanced oxygen supply due to intensified oxygen extraction by tissues. This fact is attributed to transient changes in blood rheology. Application of APSAC prevented inhibition of myocardial contractility and development of congestive heart failure in subacute MI period. TT patients demonstrated ventricular arrhythmia on MI day 1 more often though by the number of the main arrhythmia types the groups differed insignificantly. Within 1-year postmyocardial infarction period TT patients had less repeat MI and were less frequently diagnosed to develop congestive heart failure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
[Infarct size and left ventricular function in patients after thrombolytic therapy of acute myocardial infarct].
June 1989, Vnitrni lekarstvi,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
[Does intracoronary thrombolytic therapy in myocardial infarct improve left ventricular function?].
May 1985, Vnitrni lekarstvi,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
[The effect of systemic thrombolytic therapy on left ventricular contractile function and on the tolerance for physical loading in patients with an acute myocardial infarct].
January 1996, Terapevticheskii arkhiv,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
[Effectiveness of systemic thrombolytic therapy in acute myocardial infarct].
January 1995, Klinicheskaia meditsina,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
Effect of thrombolytic therapy on the incidence of early left ventricular infarct expansion in acute anterior myocardial infarction.
November 2011, Oman medical journal,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
[Effect of thrombolytic therapy in acute myocardial infarct on incidence of ventricular late potentials].
May 1991, Zeitschrift fur Kardiologie,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
Effect of early systemic thrombolytic therapy on left ventricular mural thrombus formation in acute anterior myocardial infarction.
August 1984, The American journal of cardiology,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
[Taking a position on systemic thrombolytic therapy of acute myocardial infarct].
July 1987, Orvosi hetilap,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
Effects of thrombolytic therapy on evolution of left ventricular function in acute myocardial infarction.
February 1986, Herz,
N B Perepech, and A O Nedoshivin, and A E Kutuzova, and I V Nesterova, and I E Mikhaĭlova
Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion.
March 2016, Heart (British Cardiac Society),
Copied contents to your clipboard!